New combo aims to make inoperable lung cancer operable
NCT ID NCT06449313
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tests whether giving chemotherapy plus the immunotherapy drug cemiplimab (Libtayo) before surgery can shrink tumors enough to allow surgical removal in people with stage 3 non-small cell lung cancer that has spread to certain lymph nodes (N3). About 21 participants will receive four cycles of the drug combination, then undergo surgery if the tumor shrinks. After surgery, they may receive radiation and continue cemiplimab for a year. The main goal is to see how many patients have no cancer cells left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lombardi Comprehensive Cancer Center, Georgetown University
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UVA Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine-Sitemen Cancer Center
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemiplimab (Libtayo) plus platinum-doublet chemotherapy
What this could lead to
If successful, this approach could allow more patients with advanced lung cancer to have surgery and potentially improve long-term control of the disease.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply broadly. The combination of chemo and immunotherapy can cause significant side effects, and not all tumors will shrink enough for surgery.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.